Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS, Reddy PS, Banfield C, Salganik M, Banerjee A, Gale JD, Hung KE. Sandborn WJ, et al. Among authors: banfield c. Clin Gastroenterol Hepatol. 2023 Sep;21(10):2616-2628.e7. doi: 10.1016/j.cgh.2022.12.029. Epub 2023 Jan 6. Clin Gastroenterol Hepatol. 2023. PMID: 36623678 Free article. Clinical Trial.
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Landis MN, Smith SR, Berstein G, Fetterly G, Ghosh P, Feng G, Pradhan V, Aggarwal S, Banfield C, Peeva E, Vincent MS, Beebe JS, Tarabar S. Landis MN, et al. Among authors: banfield c. Br J Dermatol. 2023 Jul 7;189(1):33-41. doi: 10.1093/bjd/ljad098. Br J Dermatol. 2023. PMID: 36972293 Clinical Trial.
Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.
Martin DA, Telliez JB, Pleasic-Williams S, Zhang Y, Tierney B, Blatnik M, Gale JD, Banfield C, Zhou Y, Lejeune A, Zwillich SH, Stevens E, Tiwari N, Kieras E, Karanam A. Martin DA, et al. Among authors: banfield c. J Clin Pharmacol. 2024 Jan;64(1):67-79. doi: 10.1002/jcph.2347. Epub 2023 Sep 29. J Clin Pharmacol. 2024. PMID: 37691236 Clinical Trial.
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis.
Hassan-Zahraee M, Ye Z, Xi L, Dushin E, Lee J, Romatowski J, Leszczyszyn J, Danese S, Sandborn WJ, Banfield C, Gale JD, Peeva E, Longman RS, Hyde CL, Hung KE. Hassan-Zahraee M, et al. Among authors: banfield c. J Crohns Colitis. 2024 Sep 3;18(9):1361-1370. doi: 10.1093/ecco-jcc/jjad213. J Crohns Colitis. 2024. PMID: 38141256 Free PMC article. Clinical Trial.
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
Kimball AB, Peeva E, Forman S, Moiin A, Khattri S, Porter ML, Mangold AR, Ghosh P, Banfield C, Oemar B. Kimball AB, et al. Among authors: banfield c. NEJM Evid. 2024 Mar;3(3):EVIDoa2300155. doi: 10.1056/EVIDoa2300155. Epub 2024 Feb 9. NEJM Evid. 2024. PMID: 38335032 Clinical Trial.
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis.
Tsamandouras N, Qiu R, Hughes JH, Sweeney K, Prybylski JP, Banfield C, Nicholas T. Tsamandouras N, et al. Among authors: banfield c. J Pharmacokinet Pharmacodyn. 2024 Jun;51(3):265-277. doi: 10.1007/s10928-024-09901-2. Epub 2024 Mar 3. J Pharmacokinet Pharmacodyn. 2024. PMID: 38431923 Free PMC article. Clinical Trial.
110 results